Assembly Biosciences Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

BST:V7B Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
30 Dec 24	Buy€48,188	Michael Houghton	Individual	3,202	€15.05
19 Dec 24	Buy€19,358,840	Gilead Sciences, Inc.	Company	940,499	€20.58
25 Nov 24	Buy€354,845	Alexander Schornstein	Individual	25,000	€14.31
18 Nov 24	Sell€616	Nicole White	Individual	40	€15.41
08 Oct 24	Buy€132,940	Alexander Schornstein	Individual	10,000	€13.29
03 Oct 24	Sell€2,111	Nicole White	Individual	157	€13.45
03 Oct 24	Sell€2,649	Jason Okazaki	Individual	197	€13.45
02 Aug 24	Sell€12,785	Jason Okazaki	Individual	981	€13.03
02 Aug 24	Sell€10,231	Nicole White	Individual	785	€13.03
05 Jul 24	Buy€103,113	Alexander Schornstein	Individual	9,000	€11.56
23 May 24	Sell€2,373	Nicole White	Individual	172	€13.80
23 May 24	Sell€7,575	Jason Okazaki	Individual	549	€13.80
23 May 24	Sell€29,209	John McHutchison	Individual	2,117	€13.80
23 May 24	Sell€331	Jeanette Bjorkquist	Individual	24	€13.80
30 Apr 24	Sell€18,645	Jason Okazaki	Individual	1,569	€11.88
30 Apr 24	Sell€14,914	Nicole White	Individual	1,255	€11.88
01 Apr 24	Sell€4,308	Jason Okazaki	Individual	354	€12.17
01 Apr 24	Sell€2,397	Nicole White	Individual	197	€12.17
01 Apr 24	Sell€1,387	Jeanette Bjorkquist	Individual	114	€12.17
01 Apr 24	Sell€14,677	John McHutchison	Individual	1,206	€12.17
27 Mar 24	Sell€4,663	Jason Okazaki	Individual	392	€11.89
18 Jan 24	Buy€470,567	Alexander Schornstein	Individual	53,756.65	€8.84

Insider Trading Volume

Insider Buying: V7B insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of V7B?
Owner Type	Number of Shares	Ownership Percentage
Hedge Funds	354,000	5.57%
Institutions	682,201	10.7%
Individual Insiders	781,587	12.3%
Public Companies	2,209,471	34.8%
General Public	2,329,027	36.6%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.9%.

Top Shareholders

Top 25 shareholders own 63.03% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
34.8%	Gilead Sciences, Inc.	2,209,471	€33.8m	74.1%	no data
11.5%	Alexander Schornstein	728,113	€11.1m	5.05%	no data
5.57%	Armistice Capital LLC	354,000	€5.4m	-24.4%	0.14%
3.15%	The Vanguard Group, Inc.	200,458	€3.1m	0%	no data
1.21%	BlackRock, Inc.	77,108	€1.2m	-0.16%	no data
1.03%	Renaissance Technologies LLC	65,624	€1.0m	19.5%	no data
0.98%	Acuitas Investments, LLC	62,315	€952.6k	24.6%	0.3%
0.74%	Geode Capital Management, LLC	47,034	€719.0k	-13.6%	no data
0.59%	Millennium Management LLC	37,553	€574.0k	-69.6%	no data
0.47%	Northern Trust Global Investments	29,824	€455.9k	158%	no data
0.4%	Federated Hermes, Inc.	25,394	€388.2k	0%	no data
0.25%	Susquehanna International Group, LLP, Asset Management Arm	15,857	€242.4k	-8.87%	no data
0.25%	FMR LLC	15,855	€242.4k	29.8%	no data
0.25%	John McHutchison	15,615	€238.7k	0%	no data
0.23%	Bridgeway Capital Management, LLC	14,500	€221.6k	0%	no data
0.21%	Acadian Asset Management LLC	13,558	€207.2k	0%	no data
0.21%	Jason Okazaki	13,316	€203.5k	2.49%	no data
0.2%	State Street Global Advisors, Inc.	12,809	€195.8k	0%	no data
0.2%	Marshall Wace LLP	12,725	€194.5k	0%	no data
0.2%	Citadel Advisors LLC	12,720	€194.4k	-0.2%	no data
0.17%	Nicole White	10,830	€165.5k	3.08%	no data
0.16%	William Delaney	9,938	€151.9k	0%	no data
0.14%	Marquette Asset Management, LLC	9,016	€137.8k	0%	0.02%
0.12%	Amundi Asset Management SAS	7,934	€121.3k	0%	no data
0.074%	American Century Investment Management Inc	4,706	€71.9k	0%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/02 17:58
End of Day Share Price	2024/12/23 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Assembly Biosciences, Inc. is covered by 15 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Brian Skorney	Baird
Raymond Deacon	Brean Capital
Madhu Kumar	B. Riley Securities, Inc.